Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection

Ravi Shrivastava,1 Remi Shrivastava,1 Bianca Johansen,1 Thibault Allain2,3 1VITROBIO Research Institute, Issoire, 63500, France; 2Laboratoire SANABEL, Paris, 75011, France; 3UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, FranceCorrespondence: Ravi Shrivastava Email rs@vit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shrivastava R, Johansen B, Allain T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	filmogen glycerol antiviral anti-cytokines anti-inflammatory covid-19 s1 rbd Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/f0bd8e3cc6fb4799871c1b31ffd2383d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0bd8e3cc6fb4799871c1b31ffd2383d
record_format	dspace
spelling	oai:doaj.org-article:f0bd8e3cc6fb4799871c1b31ffd2383d2021-12-02T15:59:22ZAnti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection1178-7031https://doaj.org/article/f0bd8e3cc6fb4799871c1b31ffd2383d2021-03-01T00:00:00Zhttps://www.dovepress.com/anti-inflammatory-and-antiviral-osmotic-polymeric-film-to-treat-covid--peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Ravi Shrivastava,1 Remi Shrivastava,1 Bianca Johansen,1 Thibault Allain2,3 1VITROBIO Research Institute, Issoire, 63500, France; 2Laboratoire SANABEL, Paris, 75011, France; 3UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, FranceCorrespondence: Ravi Shrivastava Email rs@vitrobio.comBackground: Covid-19 infection starts in the nasal cavity when viral S1 and RBD proteins bind to the host cell ACE2 receptors, the virus multiplies, causes cell lysis, and enters the circulation. This triggers a strong cytokine release and inflammation of the nasal mucosa. A multitarget approach of cleaning the nasal mucosa and suppressing chances of nasal and systemic inflammation should minimize severe respiratory consequences. Unfortunately, no such treatments are yet available.Methods: We describe the conception of an osmotic polymeric film using an in vitro nasal mucosa mimicking model, containing polymers to neutralize Covid-19 specific viral S1, RBD proteins and selected proinflammatory cytokines.Results: The filmogen barrier forms a stable and osmotic film on the nasal mucosa. Hypotonic liquid exudation from the nasal surface detaches and drains the inflammatory cytokines and other contaminants towards the film where selected polymers bind and neutralize SARS-CoV-2 spike S1 and RBD protein as well as Covid-19 disease-specific key pro-inflammatory IL-6, TNF-α, IL-10, IL-13, and GM-CSF cytokines.Conclusion: Minimizing the nasal surface concentration of pro-inflammatory cytokines and viruses should help nasal mucosa repair and avoid immune stress. This nearly instant, simple, scientific, safe, and logical approach should help attenuate Covid-19 induced systemic inflammation at an early stage without being affected by viral S1 spike protein mutations.Keywords: filmogen glycerol, antiviral, anti-cytokines, anti-inflammatory, Covid-19, S1, RBDShrivastava RShrivastava RJohansen BAllain TDove Medical Pressarticlefilmogen glycerolantiviralanti-cytokinesanti-inflammatorycovid-19s1rbdPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 1195-1206 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	filmogen glycerol antiviral anti-cytokines anti-inflammatory covid-19 s1 rbd Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	filmogen glycerol antiviral anti-cytokines anti-inflammatory covid-19 s1 rbd Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Shrivastava R Shrivastava R Johansen B Allain T Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
description	Ravi Shrivastava,1 Remi Shrivastava,1 Bianca Johansen,1 Thibault Allain2,3 1VITROBIO Research Institute, Issoire, 63500, France; 2Laboratoire SANABEL, Paris, 75011, France; 3UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, Toulouse, FranceCorrespondence: Ravi Shrivastava Email rs@vitrobio.comBackground: Covid-19 infection starts in the nasal cavity when viral S1 and RBD proteins bind to the host cell ACE2 receptors, the virus multiplies, causes cell lysis, and enters the circulation. This triggers a strong cytokine release and inflammation of the nasal mucosa. A multitarget approach of cleaning the nasal mucosa and suppressing chances of nasal and systemic inflammation should minimize severe respiratory consequences. Unfortunately, no such treatments are yet available.Methods: We describe the conception of an osmotic polymeric film using an in vitro nasal mucosa mimicking model, containing polymers to neutralize Covid-19 specific viral S1, RBD proteins and selected proinflammatory cytokines.Results: The filmogen barrier forms a stable and osmotic film on the nasal mucosa. Hypotonic liquid exudation from the nasal surface detaches and drains the inflammatory cytokines and other contaminants towards the film where selected polymers bind and neutralize SARS-CoV-2 spike S1 and RBD protein as well as Covid-19 disease-specific key pro-inflammatory IL-6, TNF-α, IL-10, IL-13, and GM-CSF cytokines.Conclusion: Minimizing the nasal surface concentration of pro-inflammatory cytokines and viruses should help nasal mucosa repair and avoid immune stress. This nearly instant, simple, scientific, safe, and logical approach should help attenuate Covid-19 induced systemic inflammation at an early stage without being affected by viral S1 spike protein mutations.Keywords: filmogen glycerol, antiviral, anti-cytokines, anti-inflammatory, Covid-19, S1, RBD
format	article
author	Shrivastava R Shrivastava R Johansen B Allain T
author_facet	Shrivastava R Shrivastava R Johansen B Allain T
author_sort	Shrivastava R
title	Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
title_short	Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
title_full	Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
title_fullStr	Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
title_full_unstemmed	Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
title_sort	anti-inflammatory and antiviral osmotic polymeric film to treat covid-19 early-stage infection
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f0bd8e3cc6fb4799871c1b31ffd2383d
work_keys_str_mv	AT shrivastavar antiinflammatoryandantiviralosmoticpolymericfilmtotreatcovid19earlystageinfection AT shrivastavar antiinflammatoryandantiviralosmoticpolymericfilmtotreatcovid19earlystageinfection AT johansenb antiinflammatoryandantiviralosmoticpolymericfilmtotreatcovid19earlystageinfection AT allaint antiinflammatoryandantiviralosmoticpolymericfilmtotreatcovid19earlystageinfection
_version_	1718385366063382528

Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection

Ejemplares similares